West Pharmaceutical Services, Inc.
WST - NYSE - $325.92 ▲ +%1.21
-
Earnings Thu 23 Jul

West opens the
books on Thursday evening.

6 analysts' median target is $315[FMP target], stock is $326, -3.4% upside potential. After Q1 +26.8% EPS beat[FMP earnings], the stock moved -1.1%.

summary below
Quick Take - in 40 seconds
B+
SELL Council 2/6 - Moonshot 49

B+ = MoonshotScore 49[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $839.2M[FMP est], EPS $2.06[FMP est]. 7 consecutive quarters of beat[FMP earnings].

$2.06 EPS Estimate Last year $2.04 - +12% YoY YoY
7 Beat Streak Expectations beaten consecutively for the last 7 quarters

Q1 EPS +26.8% beat[FMP] but the stock -1.1% D+1[FMP D+1]. Robert McMahon promised $42.7M CapEx + a sequential decline in Q4 during the Q1 earnings call[Robert McMahon capex transcript].

Watchlist

6 metrics stand out this quarter.

$43 Risk Indicator

Capex Efficiency

capex_efficiency

West continues to drive a focus on increased capital spending efficiency and remains on track with expectations of $250 million to $275 million for the year, even as it increases its revenue guidance.

"Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency. And we remain on track with our expectations of $250 million to $275 million for the year, even as we increase our revenue guidance, which I'll talk about shortly."

- Robert McMahon, CFO - Q1 FY26 Earnings Call - April 23, 2026
7% Expectation / Guide

Organic Revenue Growth Guidance

organic_revenue_growth_guidance

West has increased its full year 2026 organic revenue growth expectation to 7% to 9%, up from its previous guide of 5% to 7%.

"We now anticipate full year organic revenue growth back to our long-term construct of 7% to 9%, up from our previous guide of 5% to 7%, and adjusted EPS increased to the range of $8.40 to $8.75."

- Eric Green, CEO - Q1 FY26 Earnings Call - April 23, 2026
48% Investor Focus

Hvp Components Growth

hvp_components_growth

HVP components represents 48% of the company's total net sales and continues to be the key growth driver for West, growing 23% on an organic basis in the first quarter.

"Starting with HVP components in our proprietary Products segment, which represents 48% of our company's total net sales and continues to be the key growth driver for West. HVP components grew 23% on an organic basis in the first quarter."

- Eric Green, CEO - Q1 FY26 Earnings Call - April 23, 2026
2026 Expectation / Guide

Fy26 Revenue Guidance Increase

fy26_revenue_guidance_increase

West is increasing its revenue and adjusted EPS guidance for full year 2026 due to strong first quarter performance and the expected ongoing momentum in its business.

"As announced in the press release today, due to our strong first quarter performance and the expected ongoing momentum in our business, we are increasing our revenue and adjusted EPS guidance for full year 2026."

- Eric Green, CEO - Q1 FY26 Earnings Call - April 23, 2026
10% Investor Focus

Glp 1 Revenue Contribution

glp-1_revenue_contribution

HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter.

"HVP components GLP-1 revenues grew significantly and contributed 10% of total company sales consistent with the previous quarter."

- Eric Green, CEO - Q1 FY26 Earnings Call - April 23, 2026
26% Investor Focus

Biologics Growth

biologics_growth

This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth.

"This business continues to be a strong growth driver for our HVP components business and delivered 26% organic growth."

- Eric Green, CEO - Q1 FY26 Earnings Call - April 23, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ken Griffin, Buffett), 3 bearish (Jim Simons, Klarman, Munger), 1 neutral (Ray Dalio).

How is it calculated? ->
Ray Dalio macro - target upside -3.4%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 78
Klarman value - target upside -3.4%
Buffett quality - ROE score 5/5
Munger valuation - target upside -3.4%
Munger's Mindset character & balance sheet lens
Overvalued

Quality business, but price is high.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
77.7 RSI 77.7 overbought, 50d above
MACD
+23.00 price above 50d - support positive
50d MA
$265 stock 23.0% above - short-term support
200d MA
$262 stock 24.6% above - long-term support
Volume (10d)
+7% increase - pre-earnings positioning
Resistance
$315
Analyst median target - upgrade trigger if broken
Current
$326
Pre-earnings position
Support
$222
Invalidation - close below this is a technical breakdown
Pattern
Range
$222-$315 band - earnings breakout/breakdown trigger

Past Performance

West's last 8 quarters: 7 consecutive beats.

BEAT
Q2 FY25
$1.84 vs $1.51 est - -5.6%
BEAT
Q3 FY25
$1.96 vs $1.68 est - -3.2%
BEAT
Q4 FY25
$2.04 vs $1.83 est - +2.8%
BEAT
Q1 FY26
$2.13 vs $1.68 est - -1.1%

Q1 (April 23, 2026): EPS $2.13 vs $1.68 est[FMP], +26.8% beat. D+1 movement: -1.1%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.00 (no guidance)

Q1: EPS $2.13 vs $1.68 beat[FMP], stock -1.1% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $42.7M[FMP cashflow]. Robert McMahon Q1 transcript: "Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency."[Robert McMahon transcript]. Q1 op margin 21.0%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

"Capital expenditures were $43 million, down from $71 million in the prior year as we continue to drive a focus on increased capital spending efficiency."

- Robert McMahon, CFO - Q1 FY26 Earnings Call - April 23, 2026
Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $2.06 + CapEx discipline
Threshold: EPS > $2.06[FMP est].
Target: Break above median target $315[FMP target]; high target $340[FMP] upper bound.
Scenario B - In-Line
EPS approx $2.06 + CapEx < $42.7M
Threshold: EPS approx $2.06[FMP est], Q4 CapEx < $42.7M[FMP].
Target: Consolidation in the band between current $326[FMP] and median $315[FMP].
Scenario C - Miss
EPS < $2.00 or CapEx >= $42.7M
Threshold: EPS < $2.00[FMP estx0.97].
Target: Current $326 below SMA200 $262[FMP], if rejection continues, $222[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 6 analysts say?

Wall Street Consensus
$315
12-month median target price (-3.4% upside potential)
12
BUY
3
HOLD
0
SELL
Risk Management
$222
Invalidation level - critical support threshold
$265 - 50-day MA (above, +23.0%)
$262 - 200-day MA (above, +24.6%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - WST Q4 FY26
B+

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $2.06[FMP], CapEx threshold "below $42.7M"[Robert McMahon]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 23, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 24, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 6, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 23, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the WST earnings preview cover?

This WST (WST) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in WST earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.